Ionis PharmaceuticalsIONS
IONS
About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Employees: 927
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
18% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 50
3.02% more ownership
Funds ownership: 98.61% [Q3] → 101.63% (+3.02%) [Q4]
1% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 118
0% more funds holding
Funds holding: 349 [Q3] → 350 (+1) [Q4]
10% less capital invested
Capital invested by funds: $6.22B [Q3] → $5.61B (-$610M) [Q4]
15% less call options, than puts
Call options by funds: $26.1M | Put options by funds: $30.5M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$39
27%
upside
Avg. target
$52
69%
upside
High target
$70
128%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Needham Joseph Stringer 25% 1-year accuracy 28 / 112 met price target | 79%upside $55 | Buy Maintained | 30 Apr 2025 |
HC Wainwright & Co. Mitchell Kapoor 32% 1-year accuracy 59 / 187 met price target | 47%upside $45 | Buy Initiated | 7 Apr 2025 |
Redburn Atlantic Joshua Smith 50% 1-year accuracy 1 / 2 met price target | 27%upside $39 | Neutral Initiated | 31 Mar 2025 |
JP Morgan Jessica Fye 55% 1-year accuracy 21 / 38 met price target | 47%upside $45 | Neutral Maintained | 24 Mar 2025 |
Citigroup David Lebowitz 37% 1-year accuracy 7 / 19 met price target | 108%upside $64 | Buy Maintained | 20 Feb 2025 |
Financial journalist opinion
Based on 11 articles about IONS published over the past 30 days
Neutral
Seeking Alpha
2 hours ago
Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP & Chief Global Product Strategy Officer Beth Hougen - EVP, Finance & CFO Jonathan Birchall - SVP & Chief Commercial Officer Eugene Schneider - EVP, Chief Clinical Development & Operations Officer Conference Call Participants Jay Olson - Oppenheimer Gary Nachman - Raymond James Debjit Chattopadhyay - Guggenheim Jessica Fye - JPMorgan Chi Meng Fong - Bank of America Merrill Lynch Yaron Werber - TD Cowen David Lebowitz - Citi Mani Foroohar - Leerink Mike Ulz - Morgan Stanley Operator Good morning, and welcome to the Ionis First Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
Positive
Benzinga
2 hours ago
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge
Ionis Pharmaceuticals Inc IONS reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss.
Positive
Zacks Investment Research
6 hours ago
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
7 hours ago
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $0.98 per share a year ago.
Neutral
Business Wire
9 hours ago
Ionis reports first quarter 2025 financial results
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the first quarter ended March 31, 2025. “With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “We l.
Neutral
Business Wire
1 day ago
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven't yet found the best treatment option for them. The Ionis-sponsored survey was conducted online by The Harris Poll among 150 adults living with HAE and 228 allergists/immunologists who see HAE patien.
Positive
Zacks Investment Research
1 week ago
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Seeking Alpha
1 week ago
Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)
Ionis will announce its Q1 earnings on April 30th - in my view, the company is in a strong position and its current valuation of $4.5bn is far too low. The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG - a "blockbuster" indication. Management believes >$3bn revenues and >$2bn royalties + milestones may be achieveable long-term, with multiple new product launches for wholly-owned and partnered assets.
Positive
Zacks Investment Research
2 weeks ago
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Business Wire
3 weeks ago
Ionis to host expert panel discussion on sHTG
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated with severe hypertriglyceridemia (sHTG). Key thought leaders in lipidology, cardiology and endocrinology will join Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis, for a live discussion followed by a brief Q&A se.
Charts implemented using Lightweight Charts™